Navigation Links
Lipodissolve - Is it Safe???
Date:9/24/2007

President of National Cosmetic Dermatology Organization Urges Consumers to

Beware!

OMAHA, Neb., Sept. 24 /PRNewswire/ -- Joel Schlessinger, M.D., President of the American Society of Cosmetic Dermatology and Aesthetic Surgery (ASCDAS), responded to the recent decision by Judge David Bruns to block the proposal by the Kansas State Board of Healing Arts to ban the liposuction treatment, Lipodissolve. "This procedure is still unsafe in my estimation and has the potential to cause significant harm, especially given its poor track record in Europe, Brazil and Canada," the board-certified dermatologist and general cosmetic surgeon said.

The safety of Lipodissolve, a treatment involving a series of injections of a mixture of phosphatidylcholine and sodium deoxycholate (PC/DC) to break down body fat, has long been criticized as unstudied by medical entities. In addition to Schlessinger's statement on behalf of ASCDAS, the American Society of Plastic Surgeons and the American Society of Dermatologic Surgeons have also released statements against the use and practice of Lipodissolve. The proposed ban by the Kansas State Board of Healing Arts was the first of its kind in the United States, and followed the lead of Brazil, Canada and the United Kingdom in banning Lipodissolve treatments. "The decision to reverse the Kansas block on Lipodissolve unfortunately goes against FDA statements regarding the safe and responsible practices of cosmetic dermatology," states Schlessinger.

"I am quite concerned that this process is going on in a wide variety of unregulated settings. Many cases have come to my attention where patients suffered long-term consequences, most of the time without having any idea of the potential for problems prior to having treatments performed" said Joel Schlessinger M.D. "Additionally, the individuals administering the procedure are frequently unskilled in sterile technique, the ingredients used in the treatment are untested and the procedure remains unregulated. Consumers need to be aware that there are definite risks of complications from a procedure like Lipodissolve, which involves the injection of a foreign substance derived from cow bile into the body."

Dr. Schlessinger continued, "Lipodissolve is essentially a drug that has not been tested or FDA approved. While I do hold hope that it will eventually be studied under controlled trials, until this is done there is no way to ensure that it is safe. There is a huge industry that has been built up to promote this and they tout studies showing its safety, but all of these studies have been performed by the company selling the product. This flies in the face of solid, scientific research."

Joel Schlessinger M.D., board-certified dermatologist and general cosmetic surgeon, is the President of the American Society of Cosmetic Dermatology and Aesthetic Surgery and past president of the Nebraska Dermatology Society. He is currently working with the FDA and the Nebraska State Board of Healing Arts to regulate Lipodissolve. Interviews with Dr. Schlessinger are available and interested media may contact the company at 772-633-8337.


'/>"/>
SOURCE Joel Schlessinger, M.D.
Copyright©2007 PR Newswire.
All rights reserved

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... An April 24th article on Yahoo! Beauty discusses ... with the help of a weight loss surgery. The woman, declaring “I will not hate ... been left following her dramatic weight loss. Dr. Feiz & Associates notes that, while it ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... its new partnership with the Home Care Association of America (HCAOA). This agreement ... Private Duty Accreditation services, as well as discounts on Accreditation University (AU) educational ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage ... unmet medical needs, today announced that it will ... development program, based on its proprietary self-delivering RNAi ... (SID) 76 th Annual Meeting.  The SID ... relevant to skin health and disease through education, ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: